**Age predicts initiation of and persistence with P2Y12 inhibitor treatment after acute coronary syndrome – results from a nationwide retrospective cohort in Finland**

T. Prami1, H. Khanfir1, A. Deleskog2, P. Hasvold2, V. Kyto3,4, E. Reissell5, J. Airaksinen5

1EPID Research, Espoo, Finland • 2AstraZeneca Nordic Baltic, Södertälje, Sweden • 3University of Turku, Research Centre of Applied and Preventive Cardiovascular Medicine, Turku, Finland • 4Turku University Hospital, Heart Center, Turku, Finland • 5National Institute for Health and Welfare (THL), Helsinki, Finland • 6Turku University Hospital, Heart Center, Turku, Finland

**Background**

Secondary preventive drug therapy following acute coronary syndrome (ACS) is recommended to reduce the risk of new cardiovascular events irrespective of age at initiation. However, only limited contemporary data are available on the association of age with the initiation of and persistence with secondary preventive drug therapy, especially regarding the use of oral antithrombotic treatment (OAP) with P2Y12 inhibitors in patients with ACS.

**Purpose**

The aim of the present study was to describe ACS patients aged <75 and >75 years, and to examine and identify eventual differences in initiation of and persistence with secondary preventive drugs in an outpatient setting in Finland.

**Methods**

This observational cohort study linked patient-level data on diagnoses, interventions, and hospitalization periods from the Finnish Care Register for Health Care, and dispensed prescriptions and certain special reimbursement statuses from the Prescription Register. In order to interpret the gaps in drug exposure and persistence with treatment, data for institutionalization periods other than hospitalization (Care Register for Social Welfare), for living abroad (places of domicile), and for possible mortality (Statistics Finland) were also acquired from the authorities. The included patients had to be hospitalized for unstable angina pectoris (UAP) (ICD-10 I20.0) or acute myocardial infarction (MI; ICD-10 I21) during the years 2009 to 2013. Index event was defined as first ACS event during the observation period. Patients were classified as either OAP-treated or non–OAP-treated based on their drug purchases within 7 days after discharge from the hospital. Patients were grouped based on age at index, and divided by <75 and >75 years of age.

Baseline medication history data were searched for 120 days prior to index event hospitalization. Purchases of the secondary prevention drugs (other than OAPs) were searched for 30 days after the index date. Data on comorbidity status were retrieved for the 5 years prior to the index event.

Differences between the two age groups were tested with Pearson’s chi-squared test. Sensitivity analyses were performed with logistic regression and Cox model. Furthermore, in persistence analysis patients were further stratified into 5-year intervals at age of 65 – 85 years.

**Results**

Overall, 54,416 patients was included in the present study, of whom 29,372 (54%) were <75 years old and the remaining 25,044 (46%) patients were >75 years old. Women were more frequently represented in the older population, with 55% versus 27% (p <0.001) among the younger age group.

The ACS event was more often ST-elevation MI (33% vs. 19%, p<0.001) and invasively and lower persistence with P2Y12 inhibitors than younger patients. Age was independently associated with a lower initiation of and persistence with P2Y12 inhibitor use.

Comorbidity rates increased with age (Table 1), with hypertension and dyslipidaemia being the most common comorbidity.

The proportion of patients filling prescriptions for P2Y12 inhibitors was lower for the older patient group when compared with the patients aged 75 years or younger (34% versus 61%, respectively; p<0.001). Persistence with P2Y12 inhibitor therapy was higher for patients <75 years old, with 70% completing 1 year of treatment (Figure 1). Persistence with P2Y12 inhibitor therapy decreased with advancing age, and <50% of patients older than 85 years completed 9 months of P2Y12 inhibitor treatment following their hospital discharge (Figure 2). Moreover, the proportion of patients receiving treatment with statins (77% vs. 52%), beta-blockers (77% vs. 63%), and angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) (61% vs. 47%) at discharge decreased with age above 75 years compared with patients aged 75 years or younger (p<0.001 for all).

**Conclusions**

The proportion of ACS patients undergoing any invasive treatment and initiating treatment with P2Y12 inhibitors following their index event decreased to well below half of the population aged 75 years or younger. Patients over 75 years of age had a higher cardiovascular risk profile (history of MI and/or UAP, diabetes, heart failure, and atrial fibrillation) at baseline and lower persistence with P2Y12 inhibitors than younger patients. Age was independently associated with a lower initiation of and persistence with P2Y12 inhibitor use.

**Table 1.**

Baseline patient characteristics.

<table>
<thead>
<tr>
<th>Age &lt;75 years, (n=29,372)</th>
<th>Age &gt;75 years, (n=25,044)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean (SD)</td>
<td>62.5 (8.8)</td>
</tr>
<tr>
<td>Female gender</td>
<td>7804 (26.8)</td>
</tr>
<tr>
<td>MI</td>
<td>13,240 (45.1)</td>
</tr>
<tr>
<td>STEMI</td>
<td>9736 (33.1)</td>
</tr>
<tr>
<td>Unstable angina pectoris</td>
<td>6394 (21.8)</td>
</tr>
<tr>
<td>Angiography</td>
<td>17,788 (60.6)</td>
</tr>
<tr>
<td>PCI</td>
<td>13,844 (47.1)</td>
</tr>
</tbody>
</table>

**Comorbidity**

- Previous MI: 1154 (3.9) vs. 1955 (7.8)
- Previous unstable angina pectoris: 567 (1.9) vs. 7533 (3.0)
- Heart failure: 1132 (3.9) vs. 39321 (15.7)
- Stroke (total): 1240 (4.2) vs. 25070 (10.0)
- Hypertension: 19241 (65.5) vs. 22257 (88.9)
- Dyslipidaemia: 13922 (47.4) vs. 13416 (53.6)
- Diabetess mellitus: 6607 (22.5) vs. 6837 (27.3)
- Dementia/Alzheimer’s disease: 133 (0.5) vs. 1731 (6.9)
- Cancer: 1212 (4.1) vs. 2078 (8.3)

**Drugs at discharge**

- P2Y12 inhibitors, all: 18,027 (61.4) vs. 8472 (33.8)
- Clopidogrel: 15,893 (54.1) vs. 8084 (32.3)
- Prasugrel: 833 (2.8) vs. 84 (0.3)
- Ticagrelor: 1501 (4.4) vs. 394 (1.2)
- Statins: 25459 (86.7) vs. 16051 (64.1)
- Beta-blockers: 26325 (86.2) vs. 19326 (72.7)
- ACE inhibitor or ARB: 17989 (61.2) vs. 11800 (47.1)

**Figure 1**

Overall OAP treatment by age group at index.

**Figure 2**

P2Y12 persistence by age categories.

This study was sponsored by AstraZeneca Nordic-Baltic.

**ACE**=angiotensin-converting enzyme; **ARB**=angiotensin receptor blocker; **MI**=myocardial infarction; **NSTEMI**=non-ST-elevation myocardial infarction; **PCI**=percutaneous coronary intervention; **SD**=standard deviation; **STEMI**=ST-elevation myocardial infarction